Brind.
  1. Wenyin Shi is serving as Professor of Radiation Oncology at Thomas Jefferson University, where GBM is the target of ongoing trials.

A Phase III clinical trial overseen by the Jefferson Brain Tumor Center failed to show benefit for early initiation, leading to market consequences for the involved companies.

1 report, 1 independent Updated Jun 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A Phase III clinical trial overseen by the Jefferson Brain Tumor Center failed to show benefit for early initiation, leading to market consequences for the involved companies.

Who's involved

What this event is mainly about
Thomas Jefferson UniversityWenyin Shi

Keep exploring

Part of

Wenyin Shi is serving as Professor of Radiation Oncology at Thomas Jefferson University, where GBM is the target of ongoing trials. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped